Improving the Quality of Healthcare Provision Regarding HPV Immunization for Women with CIN2+ Lesions: The Experience of the Veneto Region in Italy
- PMID: 37112669
- PMCID: PMC10145840
- DOI: 10.3390/vaccines11040757
Improving the Quality of Healthcare Provision Regarding HPV Immunization for Women with CIN2+ Lesions: The Experience of the Veneto Region in Italy
Abstract
HPV is the most common cause of sexually-transmitted infections the world over. The aim of this study was to assess the impact of a healthcare quality improvement strategy designed to increase the rate of vaccination against HPV in women diagnosed with cervical lesions graded as CIN2 or higher (CIN2+) during routine screening. The Veneto Regional Health Service developed a 22-item questionnaire to measure the gap between ideal procedure and real practice regarding the offer of vaccination against HPV for women undergoing routine cervical screening. The questionnaire was administered to nine expert doctors, one at each of the region's Local Health Units (LHUs). An additional specific assessment concerned the quality of the related web pages available on the LHU websites. Strategies to close the gap between ideal procedure and real practice were decided collegially, and a checklist to support good practices was developed and shared with operators at the LHUs. Changes in practice were measured using data relating to women diagnosed with CIN2+ lesions extracted from the regional oncological screening database before and after the publication of a Regional Procedure on the topic. The LHUs differed considerably in how they managed each step, in terms of training for healthcare personnel, organization and assessment of the pathway from cervical screening to HPV vaccination, and in dedicated website communication. After implementing the quality improvement strategy, the proportion of women given a first dose of HPV vaccine within 3 months of being diagnosed with CIN2+ lesions at 1st-level screening rose to 50% (compared with 30.85% beforehand), and the median time elapsing between a diagnosis of CIN2+ lesion and a first dose of HPV vaccine dropped from 158 to 90 days. These findings underscore the importance of providing training to promote vaccination for general practitioners and other clinicians. The study also confirms the need for more efforts in communication to ensure that any citizen has the opportunity to access preventive healthcare.
Keywords: CIN2+; HPV vaccine; cervical screening; human papillomavirus; preventive healthcare; quality improvement.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions.Vaccine. 2012 Dec 17;31(1):109-13. doi: 10.1016/j.vaccine.2012.10.092. Epub 2012 Nov 6. Vaccine. 2012. PMID: 23137842
-
Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.PLoS Med. 2017 Sep 19;14(9):e1002388. doi: 10.1371/journal.pmed.1002388. eCollection 2017 Sep. PLoS Med. 2017. PMID: 28926579 Free PMC article. Clinical Trial.
-
Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study.Lancet Child Adolesc Health. 2018 Oct;2(10):707-714. doi: 10.1016/S2352-4642(18)30220-7. Epub 2018 Aug 8. Lancet Child Adolesc Health. 2018. PMID: 30236379 Free PMC article.
-
Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.Lancet Oncol. 2010 Mar;11(3):249-57. doi: 10.1016/S1470-2045(09)70360-2. Epub 2010 Jan 18. Lancet Oncol. 2010. PMID: 20089449 Clinical Trial.
-
What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination.Eur J Cancer. 2009 Oct;45(15):2714-21. doi: 10.1016/j.ejca.2009.07.024. Epub 2009 Aug 18. Eur J Cancer. 2009. PMID: 19695870 Review.
References
-
- IARC—Cancer Over Time. [(accessed on 8 August 2022)]. Available online: https://gco.iarc.fr/overtime/en/dataviz/trends?populations=38000&sexes=1....
-
- DGRV n. 576 del 04 Maggio 2021 “Ridefinizione del Calendario di Invito a Screening Cervicale Delle Donne Venticinquenni, Vaccinate per Papilloma Virus (HPV) Nelle Campagne Vaccinali Delle 12enni, di cui alla D.G.R. n. 772 del 27/05/2014 e D.G.R. n. 760 del 14/05/2015, in Tema di Prevenzione e Diagnosi Precoce Dei Tumori” e Successiva Modifica con DGRV n. 804 del 22 Giugno. 2021. [(accessed on 14 March 2023)]. Available online: http://bur.regione.veneto.it/BurvServices/Pubblica/DettaglioDgr.aspx?id=....
LinkOut - more resources
Full Text Sources
Miscellaneous